2511 North Loop 1604 West
United States - Map
|Full Time Employees:||1|
GenSpera Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, and other cancers. The companys prodrug development candidates comprise Mipsagargin, a prostate specific membrane antigen that is in Phase II clinical trial for the blood vessels of various solid tumors; G-115, a prostate specific antigen, which has completed pilot toxicology, as well as limited pre-clinical development stage for the treatment of prostate cancers; G-114, a prostate specific antigen for treating prostate cancers; and G-301, a human glandular kallikrein 2 for the treatment of prostate cancers. GenSpera Inc. was founded in 2003 and is based in San Antonio, Texas.
|Dr. Russell B. Richerson Ph.D.,
Interim Principal Exec. Officer, Chief Operating Officer, Interim Principal Accounting Officer and Sec.
|Dr. John T. Isaacs Ph.D.,
Co-Founder, Chairman of Scientific Advisory Board and Chief Scientific Advisor
|Dr. Samuel R. Denmeade M.D.,
Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|